Biomea Fusion, Inc. (BMEA) News
Follow Biomea Fusion, Inc. (BMEA) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 11 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Biomea Fusion Stock Falls on Termination of Proposed Public Offering
By Kelly CloonanShares of Biomea Fusion slid after the company terminated its proposed public offering of securities.The stock declined 16% to $1.44 on Wednesday. Shares are up 16% year to date.The clinical-stage diabete
EQUITY | Sep 23, 2026, 03:23 PM UTC
L
Biomea Fusion, Inc. (BMEA) Terminates Planned Public Offering
Biomea Fusion terminated its proposed public offering announced Sept. 22, citing market conditions; no securities were sold.Material DetailsContext by AI AnalystThis reverses a just-announced capital raise, highlighting
NEWS | Sep 23, 2026, 11:11 AM UTC
L
Biomea Fusion Announces Termination Of Proposed Public Offering Of Securities
Biomea Fusion, Inc. NASDAQ:BMEA
NEWS | Sep 23, 2026, 11:07 AM UTC
L
BMEA - Biomea Fusion Announces Termination of Proposed Public Offering of Securities
BMEA - Biomea Fusion Announces Termination of Proposed Public Offering of Securities
NEWS | Sep 23, 2026, 11:03 AM UTC
L
BMEA - Biomea Fusion Announces Proposed Public Offering of Securities
BMEA - Biomea Fusion Announces Proposed Public Offering of Securities
NEWS | Sep 22, 2026, 08:11 PM UTC
L
BMEA: Promising phase II diabetes results and next-gen GLP-1 data set for major readouts this year
The presentation highlighted progress on a first-in-class menin inhibitor for diabetes, showing promising phase II results in both Type 1 and Type 2 diabetes, and a next-generation GLP-1 agent with improved tolerability.
NEWS | Sep 15, 2026, 04:10 PM UTC
L
BMEA: Promising phase II data for novel diabetes therapies, with key readouts due by next year
The presentation highlighted a focused pipeline with a first-in-class menin inhibitor for diabetes and a next-generation GLP-1 agonist, both showing promising phase II results in efficacy and safety. Key readouts and reg
NEWS | Sep 15, 2026, 03:53 PM UTC
L
Biomea Fusion management to participate in upcoming investor conferences
Biomea Fusion said members of management will participate in upcoming investor conferences, according to a company announcement. The company is a clinical-stage diabetes and obesity business.
EQUITY | Sep 03, 2026, 12:07 PM UTC
L
BMEA - Biomea Fusion to Participate in Upcoming Investor Conferences
BMEA - Biomea Fusion to Participate in Upcoming Investor Conferences
EQUITY | Sep 03, 2026, 12:02 PM UTC
M
Biomea Fusion completes enrollment in Phase II COVALENT-211 diabetes trial
Biomea Fusion (BMEA) announces completion of enrollment in the COVALENT-211 Phase II trial of icovamenib in insulin-deficient Type 2 diabetes.
EQUITY | Aug 24, 2026, 11:02 AM UTC
L
Biomea Fusion doses first patient in OPAL obesity study
Biomea Fusion says the first patient has been dosed in its OPAL study evaluating icovamenib in combination with semaglutide in obesity.
EQUITY | Aug 13, 2026, 11:00 AM UTC